IDH1 and acute myeloid leukemia: In patients with R/R IDH1/2-mutant AML, ivosidenib and enasidenib have induced therapeutic responses in a considerable proportion of patients with an ORR ~40%, CR rates ~20%, and median time to CR of approximately 3 months [22,23].